

THE AMERICAN JOURNAL OF MANAGED CARE®

Publishing Staff

Senior Vice President
of Operations and Clinical Affairs
Jeff D. Prescott, PharmD, RPh

Senior Clinical Projects Manager
Ida Delmendo

Clinical Projects Manager
Cindy Spielvogel

Project Manager
Jessica Toye

Proofreaders
Griselda Demassey
Maggie Shaw

Associate Editor
Jeanne Linke

Assistant Editor
Sarah Anwar

Clinical Editor
Michael R. Page, PharmD, RPh

Designer
Julianne Costello
Associate Publisher
Justin T. Gallagher

Director of Sales
Sara Belanger

National Account Managers
Gabrielle Consola
Michael Costella

Corporate

Chairman and CEO
Mike Hennessy, Sr

Vice Chairman
Jack Lepping

President
Mike Hennessy, Jr

Chief Operating Officer/CFO
Neil Glasser, CPA/CFE

President, Managed Markets, Pharmacy,
and Rare Disease
Brian Haug

Executive Vice President
and General Manager
John Maglione

Chief Creative Officer
Jeff Brown

Human Resources Director
Shari Lundenberg

President, Pharmacy Times Continuing
Education
David Heckard

Copyright © 2016 by Managed Care
& Healthcare Communications, LLC

May 2016 – Vol. 22, No. 6, Sup.

Cost-Effectiveness of Disease- Modifying Therapies in Multiple Sclerosis: A Managed Care Perspective

Table of Contents

| | |
|---|-------------|
| Participating Faculty | S138 |
| Reports | |
| ■ Overview and Diagnosis of Multiple Sclerosis | S141 |
| Samuel F. Hunter, MD, PhD | |
| ■ Economic Burden of Multiple Sclerosis and the Role of Managed Care Organizations in Multiple Sclerosis Management | S151 |
| Gary M. Owens, MD | |
| ■ Current and Emerging Treatment of Multiple Sclerosis | S159 |
| Felecia M. Hart, PharmD, and Jacquelyn Bainbridge, BSPHarm, PharmD | |
| CE Sample Posttest | S171 |



MH

A Supplement to *The American Journal of Managed Care*

www.ajmc.com

PROJ ACE0044

Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis: A Managed Care Perspective

This supplement to *The American Journal of Managed Care* provides a clinical overview of multiple sclerosis that encompasses disease definition, epidemiology, and diagnosis. Current diagnostic criteria and phenotype definitions are described, and the profound burden the disease exerts on patients, caregivers, families, employers, health-care systems, and society is highlighted.

■ Faculty

Jacquelyn Bainbridge, BSPHarm, PharmD

Professor
Department of Clinical Pharmacy
Skaggs School of Pharmacy and Pharmaceutical Sciences
Department of Neurology
School of Medicine
Anschutz Medical Campus
University of Colorado
Aurora, Colorado

Felecia M. Hart, PharmD

Clinical Neurology Research Fellow
Department of Clinical Pharmacy
Skaggs School of Pharmacy and Pharmaceutical Sciences
University of Colorado
Aurora, Colorado

Samuel F. Hunter, MD, PhD

President
Advanced Neurosciences Institute
Franklin, Tennessee

University Director
NeuroNexus Center
Neurology Research at the Novel Pharmaceuticals Institute
Franklin, Tennessee

Clinical Assistant Professor
Department of Neurology
Vanderbilt University School of Medicine
Nashville, Tennessee

Gary M. Owens, MD

President
Gary Owens Associates
Ocean View, Delaware

■ Editorial Support

Karen Golebowski, MS

President and Principal Biomedical Writer
Write Rite, Inc
Lopatcong, New Jersey

Cynthia L. Kryder, MS, CCC-Sp

Medical Communications Consultant
Phoenixville, Pennsylvania

Elizabeth Paczolt, MD, FACNM

Medical Consultant
Churchville, Pennsylvania

■ Faculty Disclosures

These faculty report relationships with the following organizations:

Samuel F. Hunter, MD, PhD

Consultant:

AbbVie, Bayer, Genentech/Roche, Sanofi-Genzyme

Multicenter clinical research trial participation:

Adamas, Biogen, Genentech/Roche, Teva

Research grant support:

Sanofi-Genzyme

Speakers' Bureau:

Mallinckrodt, Novartis, Sanofi-Genzyme, Teva

Gary Owens, MD

Consultant:

Biogen, Genentech/Roche, Genzyme, Novartis

Honoraria:

Biogen, Genentech/Roche, Genzyme, Novartis

Jacquelyn Bainbridge, BSPHarm, PharmD, and **Felecia M. Hart, PharmD**, have no relevant financial relationships with commercial interests to disclose.

■ Editorial Support Disclosures

Karen Golebowski, MS; Cynthia L. Kryder, MS, CCC-Sp; and **Elizabeth Paczolt, MD, FACNM**, have no relevant financial relationships with commercial interests to disclose.

The American Journal of Managed Care

Publishing Staff—Jeff D. Prescott, PharmD, RPh; Ida Delmendo; and Cindy Spielvogel have no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education

Planning Staff—Dave Heckard; Maryjo Dixon, RPh; Neelam Davis, PharmD; Donna Fausak; Nathalie Harden; and Tara DeLorenzo have no relevant financial relationships with commercial interests to disclose.

Signed disclosures are on file at the office of *The American Journal of Managed Care*, Plainsboro, New Jersey.

Disclosure Policy

According to the disclosure policy of *The American Journal of Managed Care* and Pharmacy Times Continuing Education, all persons who are in a position to control content are required to disclose any relevant financial relationships with commercial interests. If a conflict is identified, it is the responsibility of Pharmacy Times Continuing Education to initiate a mechanism to resolve the conflict(s). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

Disclosure of Unapproved/Off-Label Use

The contents of this activity may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Participants should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.

The information provided in this CE activity is for continuing medical and pharmacy education purposes only and is not meant to substitute for the independent medical or pharmacy judgment of a physician or pharmacist relative to diagnostic, treatment, or management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of *The American Journal of Managed Care*, Pharmacy Times Continuing Education, or any of the companies that provided commercial support for this CE activity.